Inspire Medical Systems (INSP) EBITDA (2017 - 2026)

Inspire Medical Systems (INSP) has 10 years of EBITDA data on file, last reported at -$1.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 24.71% year-over-year to -$1.1 million; the trailing twelve-month figure through Mar 2026 stood at $51.3 million (up 3.02% YoY), and the FY2025 full-year result was $51.0 million, up 41.21% from the prior year.
• EBITDA retreated to -$1.1 million in Q1 2026, from $46.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $46.1 million in Q4 2025 to a low of -$19.5 million in Q1 2023.
• A 5-year average of -$114352.9 and a median of -$1.5 million in 2025 frame the typical range for EBITDA.
• Across the five-year window, EBITDA jumped 2875.22% in 2023 and slumped 165.03% in 2025, its largest moves.
• Tracing INSP's EBITDA over 5 years: stood at -$335000.0 in 2022, then jumped by 2875.22% to $9.3 million in 2023, then surged by 242.95% to $31.9 million in 2024, then jumped by 44.62% to $46.1 million in 2025, then slumped by 102.42% to -$1.1 million in 2026.
• Business Quant data shows INSP's EBITDA at -$1.1 million in Q1 2026, $46.1 million in Q4 2025, and $9.6 million in Q3 2025.